Schepens; Wim Bert Griet

Patent Applications and Registrations

Patent applications and USPTO patent grants for Schepens; Wim Bert Griet.The latest application filed is for "novel monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as prmt5 inhibitors".

Company Profile

5.11.12

Schepens; Wim Bert Griet - Sint Katelijne Waver BE
Schepens; Wim Bert Griet - Beerse BE
Schepens; Wim Bert Griet - Mechelen BE
Schepens; Wim Bert Griet - Mechepens BE
Schepens; Wim Bert Griet - Wetteren BE

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
6-6 bicyclic aromatic ring substituted nucleoside analogues for use as PRMT5 inhibitors Grant 11,318,157 - Wu , et al. May 3, 2	2022-05-03
Novel Monocyclic And Bicyclic Ring System Substituted Carbanucleoside Analogues For Use As PRMT5 Inhibitors App 20210371433 - Wu; Tongfei ; et al.	2021-12-02
Cyclic Dinucleotides As Sting Agonists App 20210277046 - Emanuel; Stuart ; et al.	2021-09-09
Monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as PRMT5 inhibitors Grant 11,098,062 - Wu , et al. August 24, 2	2021-08-24
Substituted nucleoside analogues for use as PRMT5 inhibitors Grant 10,898,504 - Berthelot , et al. January 26, 2	2021-01-26
Novel 6-6 Bicyclic Aromatic Ring Substituted Nucleoside Analogues For Use As Prmt5 Inhibitors App 20200360416 - Wu; Tongfei ; et al.	2020-11-19
Novel Substituted Nucleoside Analogues For Use As Prmt5 Inhibitors App 20200289539 - BERTHELOT; Didier Jean-Claude ; et al.	2020-09-17
Influenza virus neutralizing peptidomimetic compounds Grant 10,738,083 - Van Dongen , et al. A	2020-08-11
6-6 bicyclic aromatic ring substituted nucleoside analogues for use as PRMT5 inhibitors Grant 10,653,711 - Wu , et al.	2020-05-19
Novel Monocyclic And Bicyclic Ring System Substituted Carbanucleoside Analogues For Use As Prmt5 Inhibitors App 20190263833 - WU; Tongfei ; et al.	2019-08-29
Novel 6-6 Bicyclic Aromatic Ring Substituted Nucleoside Analogues For Use As Prmt5 Inhibitors App 20180243328 - Wu; Tongfei ; et al.	2018-08-30
Influenza Virus Neutralizing Peptidomimetic Compounds App 20180118788 - VAN DONGEN; Maria ; et al.	2018-05-03
HIV Membrane Fusion Inhibitors App 20140357577 - Malcolm; Bruce Albert ; et al.	2014-12-04
Amide compounds as boosters of antivirals Grant 8,664,391 - Jonckers , et al. March 4, 2	2014-03-04
5-amino-4-hydroxypentoyl amides Grant 8,592,429 - Kalayanov , et al. November 26, 2	2013-11-26
Amide compounds as boosters of antivirals Grant 8,350,048 - Jonckers , et al. January 8, 2	2013-01-08
5-amino-4-hydroxypentoyl Amides App 20120295920 - Kalayanov; Genadiy ; et al.	2012-11-22
Amide Compounds As Boosters Of Antivirals App 20110195969 - Jonckers; Tim Hugo Maria ; et al.	2011-08-11
HIV inhibiting 3,4-dihydro-imidazo[4,5-B]pyridin-5-ones Grant 7,994,187 - Kesteleyn , et al. August 9, 2	2011-08-09
Amide Compounds As Boosters Of Antivirals App 20100305073 - Jonckers; Tim Hugo Maria ; et al.	2010-12-02
Hiv Inhibiting 3,4-dihydro-imidazo[4,5-b]pyridin-5-ones App 20090170855 - Kesteleyn; Bart Rudolf Romanie ; et al.	2009-07-02

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.